NCT01976650

Safety and Efficacy of Dexamethasone (OZURDEX®) Intravitreal Implant in Korea

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 724 (actual)
• Sponsor: Allergan · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is a Post-Market Surveillance study in Korea to evaluate the safety and efficacy of dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant used to treat Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye in clinical practice.

Conditions

• Retinal Vein Occlusion

Interventions

Type	Name	Description
DRUG	dexamethasone 700 ㎍ intravitreal implant	dexamethasone 700 ㎍ (OZURDEX®) intravitreal implant treatment for Branch Retinal Vein Occlusion, Central Retinal Vein Occlusion, or non-infectious uveitis affecting the posterior segment of the eye as per local standard of care in clinical practice.

Timeline

• Start date: 2011-03-01
• Primary completion: 2015-03-01
• Completion: 2015-03-01
• First posted: 2013-11-06
• Last updated: 2016-01-13
• Results posted: 2016-01-13

Locations

1 site across 1 country: South Korea